Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Beyond Air Inc

Healthcare US XAIR

0.3798USD
-0.0062(1.61%)

Last update at 2026-06-10T20:00:00Z

Day Range

0.370.40
LowHigh

52 Week Range

0.161.49
LowHigh

Fundamentals

  • Previous Close 0.39
  • Market Cap15.72M
  • Volume284702
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-46.99300M
  • Revenue TTM3.02M
  • Revenue Per Share TTM0.06
  • Gross Profit TTM -2.14400M
  • Diluted EPS TTM-1.0

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -59.40100M -44.06000M -22.87500M -20.09680M -6.55845M
Minority interest -3.58500M -0.88200M 0.00000M - -
Net income -55.81600M -43.17700M -22.87500M -19.94250M -6.55845M
Selling general administrative 34.69M 18.41M 10.47M 8.88M 6.85M
Selling and marketing expenses - - - - -
Gross profit -0.55500M -0.58800M 0.87M 1.39M 7.72M
Reconciled depreciation 1.17M 0.35M 0.21M 0.16M 0.06M
Ebit -52.05900M -30.21000M -22.21300M -18.14194M -3.06158M
Ebitda -50.88900M -29.62200M -22.00200M -17.98253M -2.99679M
Depreciation and amortization 1.17M 0.59M 0.21M 0.16M 0.06M
Non operating income net other -7.31200M -2.57500M -0.01961M - -
Operating income -51.50400M -40.71000M -22.21400M -18.14194M -3.05855M
Other operating expenses 52.06M 30.21M 23.09M 19.53M 10.78M
Interest expense 0.03M 0.78M 0.64M 0.03M 0.00151M
Tax provision 0.00000M 0.00000M 0.00000M -0.15430M 0.00000M
Interest income - - - 1.95M 3.50M
Net interest income -0.03000M -0.77500M -0.64163M -0.03054M 0.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.55500M -0.10800M 0.64M -0.15430M -0.00153M
Total revenue 0.06M 0.15M 0.87M 1.39M 7.72M
Total operating expenses 51.50M 30.21M 23.09M 19.53M 10.78M
Cost of revenue 0.56M 0.59M - 18.14M 3.06M
Total other income expense net -7.31200M -13.07500M -0.02000M -1.92433M -3.49840M
Discontinued operations - - - - -
Net income from continuing ops -59.40100M -44.06000M -22.87473M -19.94250M -6.55845M
Net income applicable to common shares -55.81600M -43.17700M -22.54473M -20.46498M -6.55845M
Preferred stock and other adjustments - - - - -
Breakdown 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly yearly
Date 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Total assets 56.96M 68.75M 99.20M 40.53M 27.43M
Intangible assets 1.43M 1.63M 1.84M 0.37M 0.41M
Earning assets - - - - -
Other current assets 6.79M 0.34M 0.51M 0.25M 1.22M
Total liab 29.77M 26.72M 20.99M 10.06M 9.34M
Total stockholder equity 25.05M 37.91M 72.70M 30.46M 18.09M
Deferred long term liab - - - - -
Other current liab 8.26M -0.00100M 8.38M 1.80M 1.34M
Common stock 0.00500M 0.00300M 0.00300M 0.00218M 0.00161M
Capital stock 0.00500M 0.00300M 0.00300M 0.00218M 0.00161M
Retained earnings -239.69700M -179.45500M -123.63900M -80.46181M -57.58708M
Other liab - - 8.00M - -
Good will - - - - -
Other assets 0.00000M -0.00100M 0.21M 0.14M -
Cash 11.38M 29.16M 80.24M 34.63M 19.83M
Cash and equivalents - - - - -
Total current liabilities 11.57M 19.78M 10.71M 3.80M 4.87M
Current deferred revenue 0.14M 16.61M - - 0.87M
Net debt 6.46M -25.56600M -76.75500M -27.69937M -14.95393M
Short term debt 1.22M 1.15M 1.21M 0.67M 0.40M
Short long term debt 0.80M 0.78M 0.93M 0.56M 0.34M
Short long term debt total 17.84M 3.59M 3.49M 6.93M 4.88M
Other stockholder equity 264.75M 217.31M 196.24M 110.92M 75.68M
Property plant equipment - 5.00M 2.00M 0.93M 0.34M
Total current assets 43.94M 59.41M 92.94M 37.22M 26.68M
Long term investments - - - - -
Net tangible assets - 37.91M 72.70M 30.46M 17.68M
Short term investments 23.09M 16.72M - - 0.00000M
Net receivables 0.55M 0.65M 0.60M 0.47M 0.12M
Long term debt 14.72M 4.62M 8.20M 4.47M 4.34M
Inventory 2.13M 1.13M 0.35M 1.88M 5.51M
Accounts payable 1.95M 2.02M 1.13M 1.32M 2.26M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - 4.11M 5.50M - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.01500M 0.05M 0.10M -0.45257M -0.27967M
Additional paid in capital - - - - -
Common stock total equity - 0.00300M 0.00300M 0.00218M 0.00161M
Preferred stock total equity - - - - -
Retained earnings total equity - -179.45500M -123.63900M -80.46181M -
Treasury stock - -0.02500M -0.02500M -0.02500M -0.02500M
Accumulated amortization - - - - -
Non currrent assets other 0.11M 0.21M 0.21M 0.14M -
Deferred long term asset charges - - - - -
Non current assets total 13.03M 9.34M 6.25M 3.30M 0.75M
Capital lease obligations 2.32M 2.70M 2.36M 1.90M 0.20M
Long term debt total - 4.62M 8.20M 4.47M 4.34M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -16.71100M -1.45000M -0.89041M 4.47M -1.79364M
Change to liabilities 5.63M 4.55M -2.02834M -0.29855M 2.59M
Total cashflows from investing activities -20.58700M -1.45000M -0.89041M 4.42M -1.79364M
Net borrowings -1.00900M 0.37M 0.22M 5.07M 0.26M
Total cash from financing activities 2.70M 79.45M 30.33M 34.88M 1.07M
Change to operating activities 5.34M 12.16M -0.23577M -0.83150M -0.45240M
Net income -59.40100M -44.06000M -22.87500M -19.94250M -6.55845M
Change in cash -50.94300M 54.96M 9.80M 24.11M 0.62M
Begin period cash flow 90.23M 35.27M 25.46M 1.36M 0.74M
End period cash flow 39.29M 90.23M 35.27M 25.47M 1.36M
Total cash from operating activities -33.00900M -23.13400M -19.63900M -15.19237M 1.34M
Issuance of capital stock 3.71M 72.83M 30.11M 25.75M 0.80M
Depreciation 1.17M 0.35M 0.21M 0.16M 0.06M
Other cashflows from investing activities 0.00100M -0.06900M -0.07000M 4.47M -1.73716M
Dividends paid - 11.14M - 0.52M -
Change to inventory -0.78100M -0.78100M -0.78100M -0.78100M -
Change to account receivables -0.09800M 0.10M -0.42500M - -
Sale purchase of stock 3.71M 11.14M 30.11M 0.52M 0.00000M
Other cashflows from financing activities 2.70M 7.28M 7.30M 9.48M 0.30M
Change to netincome 19.83M 7.97M 4.93M 5.66M 5.70M
Capital expenditures 3.88M 1.45M 0.89M 0.04M 0.06M
Change receivables -0.09800M 0.10M -0.42500M - -
Cash flows other operating 0.97M 7.99M -0.34851M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -50.90000M 54.87M 9.80M - -
Change in working capital 5.39M 11.83M -1.20400M -1.13005M 2.13M
Stock based compensation 19.56M 7.83M 4.89M 3.58M 2.40M
Other non cash items -0.00100M 0.91M -0.70300M 0.07M -0.19701M
Free cash flow -36.88600M -24.58300M -20.52900M -15.23600M 1.28M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
XAIR
Beyond Air Inc		 -0.0062 1.61% 0.38 - - 5.20 0.89 2.24 -4.2332
ABT
Abbott Laboratories		 -2.08 2.28% 89.17 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 -5.17 1.65% 308.84 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -1.73 2.11% 80.25 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.62 1.27% 48.34 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Beyond Air Inc

900 Stewart Avenue, Garden City, NY, United States, 11530

Key Executives

Name Title Year Born
Mr. Steven Adam Lisi CEO & Chairman 1971
Mr. Amir Avniel Co-Founder, Chief Bus. Officer & Director 1974
Mr. Douglas Quinton Larson CFO, Principal Financial Officer & Principal Accounting Officer 1971
Mr. Michael A. Gaul Chief Operating Officer 1955
Edward Barger Head of Investor Relations NA
Mr. Adam Newman Chief Legal Officer & Gen. Counsel NA
Ms. Rebecca Van Doren Head of Sales NA
Ms. Kori-Ann Taylor Head of Marketing NA
Prof. Andrew R. Colin M.D. Chief Medical Officer & Member of Scientific Advisory Board NA
Dr. Giora Davidai M.D. Chief Medical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.